Current pathways for epidemiological research in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue SUPPL1, 2013, Pages 33-43

  Factor Litvak, Pam ^a   Al Chalabi, Ammar ^b   Ascherio, Alberto ^c   Bradley, Walter ^d   Chío, Adriano ^e   Garruto, Ralph ^f   Hardiman, Orla ^g   Kamel, Freya ^h   Kasarskis, Edward ⁱ   McKee, Ann ^j   Nakano, Imaharu ^k   Nelson, Lorene M ^l   Eisen, Andrew ^m  

^a Mailman School of Public Health ^*  (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f BINGHAMTON UNIVERSITY   (United States)

^g TRINITY COLLEGE DUBLIN   (Ireland)

^h NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k JICHI MEDICAL UNIVERSITY   (Japan)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

ALS; Case control study; Center based; Guamanian ALS; Multicenter study; Population based study

Indexed keywords

2 AMINO 3 METHYLAMINOPROPIONIC ACID; BIOMATERIAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CASE CONTROL STUDY; CYANOBACTERIUM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LIFESTYLE; MILITARY SERVICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; BRAIN INJURY; DISEASE COURSE; RISK FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INJURY, CHRONIC; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EPIDEMIOLOGIC STUDIES; GENE-ENVIRONMENT INTERACTION; HUMANS; RISK FACTORS;

EID: 84877854654     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.778565     Document Type: Article

References (78)

1. Armon C. An evidence based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 2003; 22: 217-28.
2. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial'Clinical limits of amyotrophic lateral sclerosis'workshop contributors. J Neurol Sci. 1994; (Suppl); S96-107.
3. McGuire V, Nelson LM. Epidemiology of ALS. In: Mitsumoto H, Przedborski S, Gordon PH, editors. Amyotrophic Lateral Sclerosis. New York: Taylor and Francis; 2006. pp 17-41.
4. Logroscino G, Traynor BJ, Hardiman O, Chio A, Couratier P, Mitchell, JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008; 79: 6-11.
5. O'Toole O, Traynor BJ, Brennan P, Sheehan C, Frost E, Corr B, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry. 2008; 79: 30-2.
6. Donaghy C, O'Toole O, Sheehan C, Kee F, Hardiman O, Patterson V. An all-Ireland epidemiological study of MND, 2004-2005. Eur J Neurol. 2009; 16: 148-53.
7. Yeo L, Lynch C, Hardiman O. Validating population based registries for ALS: how accurate is death certifi cation? J Neurol. 2010: 257: 1235-9.
8. Donaghy C, Clarke J, Patterson C, Kee F, Hardiman O, Patterson V, et al. The epidemiology of motor neuron disease in Northern Ireland using capture-recapture methodology. Amyotroph Lateral Scler. 2010; 11: 374-8.
9. Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2012; 83: 102-8.
10. Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011; 76: 1263-9.
11. Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population based mortality study. Neurology. 2009; 72: 1640-5.
12. Cronin S, Hardiman O, Traynor B. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007; 68: 1002-7.
13. Logroscino G, Traynor BJ, Hardiman O, Chi ò A, Mtchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010; 81: 385-40.
14. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, et al. Amyotrophic lateral sclerosis in south-east England: a population based study. The south-east England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology. 2007; 29: 44-8.
15. Beghi E, Logroscino G, Chi ò A, Hardiman O, Mtchell D, Swingler R, et al. The epidemiology of ALS and the role of population based registries. Biochim Biophys Acta. 2006; 1762: 1150-7.
16. Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011; 82: 1165-70.
17. Forbes RB, Colville S, Parratt J, Swingler RJ. Incidence of motor neuron disease in Scotland. J Neurol. 2007; 254: 866-9.
18. Armon C. Sports and trauma in amyotrophic lateral sclerosis revisited. J Neurol Science. 2007; 262: 45-53.
19. Chia A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R, et al. Epidemiology of ALS in Italy: a 10-year prospective population based study. Neurology. 2009; 72: 725-31.
20. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AHM, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006; 253: 1642-3.
21. Hanby MF, Scott KM, Scotton W, Wijesekera L, Mole T, Ellis CE, et al. The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain. 2011; 134: 3454-7.
22. Al-Chalabi A, Lewis CM. Modeling the effects of penetrance and family size on rates of sporadic and familial disease. Human Heredity. 2011; 7: 281-8.
23. Okamoto K, Kobashi G, Washio M, Sasaki S, Yokoyama T, Myake Y, et al. Descriptive epidemiology of amyotrophic lateral sclerosis in Japan, 1995-2001. J Epidemiol. 2005; 11: 1520-3.
24. Doi Y, Yokoyama T, Tango T, Takahashi K, Fujimoto K, Nakano I. Temporal trends and geographic clusters of mortality from amyotrophic lateral sclerosis in Japan, 1995-2004. J Neurol Sci. 2010; 298: 78-84.
25. Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, Nakano I, et al. Age at onset infl uences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2009; 276: 163-9.
26. Garruto RM, Yanagihara R, Gajdusek DC. Disappearance of high incidence amyotrophic lateral sclerosis and Parkin-sonism-dementia on Guam. Neurology. 1985; 35: 193-8.
27. Garruto RM. Pacifi c paradigms of environmentally induced neurological disorders: clinical, epidemiological and molecular perspectives. NeuroToxicology. 1991; 12: 347-8.
28. Plato CC, Garruto RM, Galasko D, Craig UK, Plato M, Gamst A, et al. Amyotrophic lateral sclerosis and Parkinsonismdementia complex of Guam: changing incidence rates during the past 60 years. Amer J Epidemiol. 2003; 157: 149-57.
29. Kihira T, Yoshida S, Kondo T, Iwai K, Wada S, Morinaga S, et al. An increase in ALS incidence on the Kii Peninsula, 1960-2009: a possible link to change in water source. Amyotroph Lateral Scler. 2012: 13: 347-50.
30. Kuzuhara S, Kokubo Y Atypical Parkinsonism of Japan: Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia complex of the Kii Peninsula of Japan (Muro Disease): An update. Movement Disorders. 2005; 20(Suppl 12): S108-13.
31. Strong MJ, Wolff AV, Wakayama I, Garruto RM. Aluminum-induced chronic myelopathy in rabbits. NeuroToxicology. 1991; 12: 9-22.
32. Lynch D, Wanglund C, Spathis R, Chan CW, Reiff DM, Lum JK, et al. The contribution of mitochondrial dysfunction to a gene-environment model of Guamanian ALS and PD. Mitochondrion. 2007; 8: 109-16.
33. Reiff DM, Spathis R, Chan CW, Vilar MG, Sankaranarayanan K, Lynch C, et al. Inherited and somatic mitochondrial DNA in Guam amyotrophic lateral sclerosis and Parkinsonism-dementia. Neurological Sciences. 2011; 32: 883-92.
34. Hermosura MC, Garruto RM. TRPM7 and TRPM2-candidate susceptibility genes for western Pacifi c ALS and PD? Biochimica et Biophysica Acta. 2007; 1772: 822-35.
35. Hara K, Kokubo Y, Ishiura H, Fukuda Y, Miyashita A, Kuwano R, et al. TRPM7 Is Not Associated With Amyotrophic Lateral Sclerosis-Parkinsonism Dementia Complex in the Kii Peninsula of Japan. Am J Med Genet Part B. 2010; 153: 310-3.
36. Bradley WG, Cox PA. Beyond Guam: BMAA and sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; (Suppl 2): 1-126.
37. Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnifi ed cyanobacterial neurotoxins and neurodegenerative disease in Guam. PNAS. 2004; 101: 12228-31.
38. Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol Scand. 2009; 120: 216-225.
39. Brand LE, Pablo J, Compton A, Hammerschlag N, Mash DC. Cyanobacterial blooms and the occurrence of the neurotoxin beta-N-methylamino-L-alanine (BMAA) in South Florida aquatic food webs. Harmful Algae. 2010; 2: 620-35.
40. Caller TA, Doolin JW, Haney JF, Murby AJ, West KG, Farrar HE, et al. A cluster of amyotrophic lateral sclerosis in New Hampshire: a possible role for toxic cyanobacteria blooms. Amyotrph Lateral Scler. 2009; 10(Suppl 2): 101-8.
41. Caller TA, Field NC, Chipman JW, Shi X, Harris BT, Stommel EW. Spatial clustering of amyotrophic lateral sclerosis and the potential role of BMAA. Amyotroph Lateral Scler. 2012; 13: 25-32.
42. Horner RD, Grambow SC, Coffman CJ, Lindquist JH, Oddone EZ, Allen KD, et al. Amyotrophic lateral sclerosis among 1991 Gulf War veterans: evidence for a time-limited outbreak. Neuroepidemiology. 2008; 31: 28-32.
43. Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz, et al. Prospective study of military service and mortality from ALS. Neurology. 2005; 64: 32-7.
44. IOM (Institute of Medicine). Gulf War and Health, Volume 8: Update of Health Effects of Serving in the Gulf War. Washington, DC: The National Academies Press, 2010.
45. Nelson LM, van den Eeden SK, Tanner CM, Bernstein AL. Incidence of amyotrophic lateral sclerosis in a multiethnic health care organization. Neuroepidemiology. 2010; 34: 276.
46. Albers K, Nelson LM, Tanner CM, McGuire V, Popat R, Bernstein AL, et al. Lead exposure and amyotrophic lateral sclerosis in a northern California population. 61st Annual Meeting of the American Academy of Neurology, World Federation of Neurology (Seattle, WA, 25 April-2 May). 2009 PM(C)ID: none.
47. Weisskopf MG, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol. 2004; 160: 26-33.
48. Ascherio A, Weisskopf MG, O'Reilly EJ, Jacobs EJ, McCullough ML, Calle EE, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol. 2005; 57: 104-10.
49. Wang H, O'Reilly É J, Weisskopf MG, Logroscino G, McCullough ML, Schatzkin A, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from fi ve prospective studies. Amer J Epidemiol. 2011; 173: 595-602.
50. Wang H, O'Reilly EJ, Weisskopf MG, Logroscino G, McCullough ML, Thun MJ, et al. Smoking and risk of amyo-trophic lateral sclerosis: a pooled analysis of fi ve prospective cohorts. Arch Neurol. 2011; 68: 207-13.
51. Fang F, Bellocco R, Hernan MA, Y e WM. Smoking, snuff dipping and the risk of amyotrophic lateral sclerosisL a prospective cohort study. Neuroepidemiology. 2006; 27: 217-21.
52. Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler D P. Lead exposure and amyotrophic lateral sclerosis. Epidemiology. 2002; 13: 311-9.
53. Kamel F, Umbach DM, Munsat TL, Shefner JM, Sandler DP. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology. 1999; 18: 194-202.
54. Chen H, Richard M, Sandler DP, Umbach DM, Kamel F. Head injury and amyotrophic lateral sclerosis. Amer J Epidemiol. 2007; 166: 810-6.
55. Fang F, Quinlan P, Y e W, Barber MK, Umbach DM, Sandler DP, et al. Workplace exposures and the risk of amyo-trophic lateral sclerosis. Environ Health Perspect. 2009; 117: 1387-92.
56. Fang F, Kwee LC, Allen KD, Umbach DM, Y e WM, Watson M, et al. Association between blood lead and the risk of amyotrophic lateral sclerosis. Amer J Epidemiol. 2010; 171: 1126-33.
57. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encepha-lopathy in athletes: progressive tauopathy following repetitive head injury. J Neuropath Exp Neurol. 2009; 68: 709-35.
58. Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G. ALS in Italian professional soccer players: the risk is still present and could be soccer-specifi c. Amyotroph Lateral Scler. 2009; 10: 205-9.
59. McKee A, Gavett BE, Stern R, Nowinski CJ, Cantu RC, Kowall NW, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropath Exp Neurol. 2010; 69: 918-29.
60. Gavett B, Stern R, Cantu R, Nowinski CJ, McKee AC. Mild traumatic brain injury: a risk factor for neurodegeneration. Alzheimer's Research and Therapy. 2010; 2: 18.
61. Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population based study. Eur J Neurol. 2009; 16: 745-51.
62. Byrne S, Elamin M, Bede P, Hardiman O. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. Journal of Neurology, Neurosurgery, and Psychiatry. 2012; 83: 365-7. Epub 2012/03/09. PubMed PMID: 22399794.
63. Mulder DW, Kurland LT, Offord KP, Beard CM. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology. 1986; 36: 511-7.
64. Williams DB, Floate DA, Leicester J. Familial motor neuron disease: differing penetrance in large pedigrees. J Neurol Sci. 1988; 86: 215-30.
65. Huisman MH, de Jong SW, Verwiis MC, Schelhaas HJ, van der Kooi AJ, de Visser M, et al. Family history of neu-rodegenerative and vascular diseases in ALS: a population based study. Neurology. 2011; 77: 1363-9.
66. Fallis BA, Hardiman O. Aggregation of neurodegenerative disease in ALS kindreds. Amyotroph Lateral Scler. 2009; 10: 95-8.
67. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9ORF72 repeat expansion: a population based cohort study. Lancet Neurol. 2012; 11: 232-40.
68. van Blitterswijk M, DeJesus-Hernandez M, Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other non-coding repeat expansion disorders? Current Opinion Neurology. 2012; 6: 689-700.
69. de Jong SW, Huisman MH, Sutedia NA, van der Koioi AJ, de Visser M, Schelhaas HJ, et al. Smoking, alcohol consumption and the risk of amyotrophic lateral sclerosis: a population based study. Amer J Epidemiol. 2012; epubub ahead of print.
70. Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in males with amyotrophic lateral sclerosis. J Neurol 2012; epub ahead of print.
71. Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011; 258: 238-43.
72. Drory VE, Bronipolsky T, Artamonov I, Nefussy B. Infl uence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008; 273: 81-3.
73. Nefussy B, Hirsch J, Cudkowicz ME, Drory VE. Gender based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Sci. 2011; 300: 23-7.
74. Dupuis L, Pradat PF, Ludolph AC, Loeffl er JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011; 10: 74-82.
75. Reiff DM, Spathis R, Chan CW. Inherited and somatic mitrochondrial DNA mutations in Guam amyotrophic lateral sclerosis and Parkinsonism-dementia. Neurol Sci. 2011; 32: 883-92.
76. Kihira T, Yoshida S, Kondo T, Iwai K, Wada S, Morinaga S, et al. An increase in ALS incidence on the Kii Peninsula, 1960-2009: a possible link to change in drinking water source. Amyotroph Lateral Scler. 2012; 13: 347-50.
77. Ishiura H, Takahashi Y, Mitsui J, Yoshida S, Kihira T, Kokubo Y, et al. C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Arch Neurol. 2012; 69: 1154-8. Epub 2012/05/29. PubMed PMID:22637429.
78. Sienko DG, Davis JP, Taylor JA, Brooks BR. Amyotrophic lateral sclerosis: a case-control study following detection of a cluster in a small Wisconsin community. Arch Neurol. 1990-47: 38-41.